

JOURNAL OF DYNAMICS

AND CONTROL

VOLUME 8 ISSUE 9

THE OPIOID CRISIS: COMPREHENSIVE APPROACHES TO PREVENTION AND TREATMENT

Sungjemrenla I Jamir¹, Shiny Ahmed², Priyam Jyoti Das^{1*}, Pdiangmon Kyndait¹, Juganta Kumar Kalita¹, Sandip Mandal¹, Moksood Ahmed Laskar¹

¹Faculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati - 781026, Assam, India

²Royal School of Pharmacy, The Assam Royal Global University, NH-37, Betkuchi, Guwahati -781035, Assam, India.

THE OPIOID CRISIS: COMPREHENSIVE APPROACHES TO PREVENTION AND TREATMENT

Sungjemrenla I Jamir¹, Shiny Ahmed², Priyam Jyoti Das^{1*}, Pdiangmon Kyndait¹, Juganta Kumar Kalita¹, Sandip Mandal¹, Moksood Ahmed Laskar¹

¹Faculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati - 781026, Assam, India

²Royal School of Pharmacy, The Assam Royal Global University, NH-37, opp. Tirupati Balaji Temple, Betkuchi, Guwahati - 781035, Assam, India.

*Corresponding Author: priyamjyotidas97@gmail.com

ABSTRACT: The opioid crisis represents a deep public health emergency driven by abuse both of prescription and illicit opioids, leading to accelerating rates of addiction, overdose, and mortality. The review summarizes the complex nature of the epidemic, moving from historical roots to current trends through an array of deployed strategies in combating the various effects. This review therefore emphasizes that, in emphasizing evidence-based prevention techniques, innovative treatment modalities, and comprehensive policy initiatives, reducing harm from opioids requires a multi-faceted approach. Key response elements include access expansion to medication-assisted treatments, use of intensive prescription monitoring programs, and inspiration of community-based policies and practices that address the root socioeconomic causes of poor health. Further, the review brings to light that healthcare professionals, and more so pharmacists, play a very important role in the education of the patients, management of prescriptions, and provision for rescue-type interventions, such as naloxone. This review is an advocate for a multiagency approach that involves health, education, and social services with the hope that this may shed light on effective intervention and recovery options against the backcloth of the current opioid crisis. Eventually, these observations call for continuous research, changes in policy, and community dedication to the many problems produced by this crisis.

KEYWORDS: Opioid Crisis, Opioid Addiction, Prescription Opioids, Addiction Treatment, Substance Use Disorder.

1. INTRODUCTION:

The opioid crisis is a severe public health emergency characterized by an increased misuse of opioids, addiction, and overdose leading to deaths. Over the past few years, this crisis has evolved which is driven by various social, economic, and medical factors. Understanding the complex nature of the opioid crisis is essential for developing effective interventions and policies.

The opioid crisis is fundamentally driven by economic and social changes, with opioids often used as a refuge from trauma, disadvantage, and isolation [1][2]. It is a complex issue rooted in inappropriate prescriptions, lack of understanding of long-term effects, misuse, abuse, and dependence, and requires urgent action to address these issues [3]. Expanding access to opioid medications and improving treatment retention, including addressing psychiatric comorbidities, are crucial for preventing fatalities and achieving recovery in the opioid crisis [4].

Good intentions to improve pain and suffering led to increased prescribing of opioids, contributing to misuse and even death [5]. In order to successfully address neurobiological vulnerabilities and socioeconomic determinants of health in the context of the opioid crisis, advancements in fundamental science, therapeutic development, and public health strategies are needed. The crisis involves neurobiological vulnerabilities and the addictive properties of opioids. Effective treatments for opioid use disorder (OUD) exist but are underutilized [6]. A multifaceted public health approach utilizing primary, secondary, and tertiary opioid addiction prevention strategies is crucial to reduce opioid-related morbidity and mortality effectively [7].

Pharmacists and other healthcare professionals play a crucial role in managing the crisis through patient education, medication reviews, and distribution of naloxone [8]. There is a need for the development of non-addictive pain medications and new treatments for OUD. Collective efforts among various academic, government, and industrial partners are essential to combat this crisis [9].

1.1. Historical context and evolution of the epidemic

The opioid crisis was significantly triggered by the introduction and aggressive marketing of OxyContin in 1996, which led to widespread overprescription and misuse of opioid medications [10]. The history, culture, mythology, religion, biology, genetics, and psychology of opioid use are crucial for understanding and addressing the current opioid epidemic [5]. Historical use of opioids dates back thousands of years, with opium being used as a pain reliever across various cultures. The modern crisis has roots in both historical and recent practices of opioid use and prescription [11]. Good intentions to improve pain and suffering led to increased prescribing of opioids, contributing to misuse and even death [5].

Pharmaceutical companies played a crucial role in the crisis by promoting opioids aggressively and downplaying their addictive potential. This led to increased availability and misuse of prescription opioids [12]. The opioid/overdose crisis is rooted in pharmaceutical misconduct, despair due to deindustrialization, and increased occupational pain, influenced by the "one-sided class war" and weakened institutions [13]. Economic and social upheaval, including deindustrialization and increased occupational pain, have also contributed to the crisis. Opioids became a refuge for individuals facing physical and psychological trauma, isolation, and hopelessness [1]. The crisis is also linked to broader social determinants of health, such as poverty and lack of social support, which exacerbate the vulnerability to opioid misuse [6].

Initially driven by prescription opioids, the crisis has evolved to include heroin and illicit synthetic opioids like fentanyl, which are more potent and deadly [4]. The misuse of opioids has shifted from medical prescriptions to illicit drugs as regulations tightened on prescription practices [10]. Effective interventions require a multifaceted approach, including better prescription practices, increased access to treatment for opioid use disorder (OUD), and addressing underlying social and economic issues [14]. Policies such as prescription monitoring programs and guidelines for opioid prescribing have been implemented to curb the misuse of opioids, but these measures alone are insufficient [10]. *1.2. Importance of addressing the Opioid crisis comprehensively*

A comprehensive public health approach is essential, combining neuroscience, pharmacology, epidemiology, treatment services, and prevention across healthcare, justice, education, and social service systems [15]. A comprehensive approach involving community involvement, professional knowledge, and strong preventative initiatives is needed to address the opioid issue [16].

Since the opioid problem is closely related to social and economic upheaval, interventions addressing the wider socioeconomic determinants of health, such isolation and concentrated poverty, are necessary [15]. Simplistic measures to cut access to opioids are insufficient; a broad focus on suffering and structural determinants is necessary for effective intervention [1].

In order to combat the opioid issue, healthcare facilities must implement programs including community collaborations, standardized screening, and modifications to prescribing practices [17]. Learning health systems, such as the Veterans Administration, are uniquely positioned to address the opioid crisis by integrating care and targeting multiple clinical concerns simultaneously [18]. Using real-time public health data to inform decision-making and program implementation is a key strategy in a comprehensive approach [16].

1.3. Objectives of the review

The objectives of this review are to provide a thorough understanding of the opioid crisis by defining its scope and origins, exploring its impact on public health, and analyzing epidemiological trends. The review aims to evaluate evidence-based prevention strategies, discuss various treatment approaches, and examine policy and legislative measures addressing the crisis. Additionally, it highlights innovative solutions, identifies challenges and barriers to effective intervention, and advocates for a multifaceted and coordinated approach that includes continuous research, policy development, and community engagement to mitigate the opioid epidemic.

2. ORIGINS AND EPIDEMIOLOGY:

Prescription opioid use and misuse is common among adolescents and young adults, often associated with additional substance abuse [19]. Opioid addiction has its roots in legal, prescription medication, increasing the exposed population and providing additional drug accessibility for addicts [20]. The opioid epidemic has created a crisis with 4% of the adult US population misuses prescription opioids, and over 33,000 deaths were attributable to overdose in 2015 [21]. Opioid prescriptions have fallen, but harms to pain patients and overdose deaths have risen due to an imbalance between strong prescription control and weak pain and addiction treatment expansion [22]. Heroin use is dominant in Australia, China, India, and Myanmar, with divergent trends in China and India.

The opioid crisis is caused by a combination of supply- and demand-side factors, with regulations reducing prescribing but may not impact root causes and may lead to greater use of harmful substances obtained in illicit markets [23]. Fentanyl and its analogues have virtually displaced traditional opioids, such as heroin, in some places, increasing the risk of fatal overdose [24]. Heroin and synthetic opioids contribute to the majority of opioid overdose deaths, making them a key factor in the opioid crisis [25]. Heroin use is dominant in Australia, China, India, and Myanmar, with divergent trends in China and India [26].

The opioid crisis is fundamentally fuelled by economic and social upheaval, with opioids serving as a refuge from physical and psychological trauma, disadvantage, isolation, and hopelessness [1]. Economic distress, family distress, persistent population loss, and opioid supply factors are all associated with significantly higher drug mortality rates [27]. Alarming and potentially correlated trends of opioid use and suicidality among American Indian and Alaska Native populations were found [28]. A correlation exists between opioid overdose mortality and poor socioeconomic position, with susceptible populations including those lacking health insurance, jailed persons, and those living in poverty [29]. Studies indicate that married persons and those with coresident children have a reduced likelihood of engaging in opioid use behaviours. Conversely, socially isolated people who do not have children are more vulnerable to changes in time and patterns in the abuse of opioids and heroin [30]. Social determinants that contribute to the opioid crisis include lack of education and economic opportunities, poor working conditions, and low social capital in disadvantaged communities [31]. Addressing modifiable social determinants like barriers to mental health services and homelessness is important to reduce polysubstance use and overdose deaths [32].

3. IMPACT ON PUBLIC HEALTH:

The opioid issue has grown to be a serious public health disaster that is overwhelming healthcare systems worldwide and causing extensive harm [33]. Prescription opioids like oxycodone and hydrocodone, as well as illegal substances like heroin and synthetic opioids like fentanyl, are examples of opioids that are associated to rising rates of addiction, overdose, and fatalities [7][34]. The most notable effect of rising opioid usage is overdosing mortality, but there are other effects as well. With potential sex disparities over the lifetime, are a major cause of mortality in the United States, with opioids like fentanyl and heroin and stimulant drugs like methamphetamine and cocaine being the most common causes. The first wave of opioid prescriptions and prescription-related mortality

from natural and semi-synthetic opioid overdoses started in the 1990s [35]. According to conventional wisdom, the second wave began in 2010 and is distinguished by a sharp increase in heroin overdose deaths [35][36]. The most recent wave involved a sharp rise in synthetic opioid overdose deaths in 2013, primarily from fentanyl generated illegally [35][37]. More than 70% of opioid overdose death was found only in Unites states in which males were shown to have higher overall overdose mortality than females [37]. Between 1999 - 2019, the United States lost about 500,000 people due to opioid overdoses from both legally prescribed and illegal obtained drugs [35]. Over 145 000 opioid-related deaths and over 5 million nonfatal overdoses among OUD (Opioid Use Disorder) patients between 2021 and 2023 [38].





Fig. 2: United States, 2002–2022: Age-adjusted rate of drug overdose deaths by sex [39]. Opioid addiction is chronic because the intravenous drug users share needles, relapsing illness that frequently results in serious health repercussions, including infectious diseases

like HIV and hepatitis C [40]. Apart from the immediate health consequences, the opioid crisis also heavily strains the public health system. Over the past ten years, the use of opioids during pregnancy has skyrocketed, posing a serious threat to public health and the prescription, illicit, and opioid replacement treatment use among women is also on the rise. These medications have been linked to a number of obstetrical issues, such as stillbirth, oligohydramnios, premature delivery, intrauterine growth restriction, and maternal mortality. Important neonatal consequences include neonatal abstinence syndrome (NAS) and an elevated risk of mortality [41]. The statistics also show that many non-fatal overdoses occur for every opioid-related death, which can result in long-term health issues like hypoxic, brain injury and persistent infections [42]. Also, the opioid crisis has put a tremendous strain on healthcare systems, increasing the number of overdose patients in emergency rooms and necessitating long-term treatment for opioid use disorder [42]. Due to this issue, the need for first responders and emergency medical services is also rising due to the growing necessity for overdose interventions like naloxone delivery [43]. The opioid epidemic has severe societal costs like for opioid use disorder (\$471 billion) and fatal opioid overdose (\$550 billion) incurred \$1,021 billion in economic costs in the United States alone between 2001 and 2017 as a result of medical expenses, lost productivity, addiction treatment, and engagement with the criminal justice system [44].

The most stigmatized illnesses are illicit drug use disorders, and it is significantly hindering access to and completion of treatment. It is crucial that we comprehend the causes of stigma and how it influences policies and treatments for opioid use disorders in light of the sharply increasing harms associated with opioid use [45]. The stigma surrounding OUD is not unique; rather, it interacts with and exacerbates marginalization related to socioeconomic status, race, gender, ethnicity, sexual orientation, and age [46][47]. This is especially crucial in light of the opioid crisis, which has disproportionately impacted the community's area with high rates of poverty, rising income disparity, and limited access to social capital [48]. Research indicates that the stigma attached to OUD serves as a direct deterrent for people considering getting treatment. Many OUD sufferers are avoiding to take therapy or avoiding to take treatment completely out of embarrassment or fear of judgment [49] and sometimes inside the healthcare system can also take the form of biased views from medical professionals, which can result in inadequate care or a refusal to administer the proper treatment, especially for patients requiring medication-assisted treatment [50]. Treatment outcomes may be negatively impacted by the stigmatization of OUD because people who absorb these unfavourable society perceptions may feel hopeless and less worthy of themselves, which can impact their efforts to heal [51]. In order to improve treatment availability and recovery outcomes for people with opioid use disorders, stigma must be addressed. Campaigns for public education that stress the medical aspect of addiction, encourage compassion, and emphasize the efficacy of treatment can aid in changing society perceptions [52]. We can also foster a more accepting atmosphere by lessening stigma, which will enable people with OUD to seek treatment without worrying about the fear of discrimination or judgement [52].

4. PREVENTION STRATEGIES:

4.1. Education and awareness campaigns targeting both healthcare providers and the public School-based prevention programs are a great way to teach teenagers about the risks associated with drug use and to give them useful coping and decision-making skills. Drug Abuse Resistance Education (DARE) is one program that has been adopted in many schools to help reduce teenage drug usage. These initiatives can successfully lower students' risk of drug use, increase their understanding of the dangers of drug use, and provide valuable rejection skills [52]. Campaigns to raise awareness in the community is

also another method to increase community knowledge of the risks of drug use and lessen the stigma attached to addiction or about the aid of the availability of treatment and support resources for individuals battling addiction. Parents, community leaders, and teenagers can all be the target audience for these initiatives, which offer tools and information on prevention and therapy. They can aid in encouraging healthy habits and give people the resources they need to recognize and deal with possible drug issues [53].

4.2. Prescription drug monitoring programs (PDMPs)

PDMPs have been implemented statewide in an attempt to regulate the dispensing of prescription medicines and the addiction that follows. It often gathers and retains data regarding the kind and quantity of prescription drugs that are given to patients. This information can then be used by pharmacies, other prescribers, law enforcement, and healthcare providers to control how the drugs are used [54][55]. The PDMP is being used by healthcare practitioners in many different ways, all of which are good for the healthcare system. According to a survey, prescribers have been using the PDMP for administrative tasks like confirming the prescription history and the status of current refill requests [56]. It is even used in pharmacy procedures to control prescription opioids and prevent overprescription. Pharmacy systems are connected with the PDMP model, and pharmacies play a significant role in the management of prescription data. In an effort to prevent improper prescription patterns, the pharmacists would frequently get in touch with the prescribers to confirm the PDMP data and assess the information beforehand [57].

4.3. Guidelines for opioid prescribing

In 2016 "Guideline for Prescribing Opioids for Chronic Pain" was developed by the Centers for Disease Control and Prevention (CDC) to assist medical professionals in making well-informed decisions regarding the use of opioids. These guidelines urge the use of non-opioid alternatives whenever possible and advise restricting opioid prescriptions to the lowest effective dose and shortest time required for acute pain [58]. This guideline updated and expanded in the clinical practice to offer evidence-based recommendations for the prescription of opioid pain medication for outpatients who are at least 18 years old for acute, subacute, and chronic pain [59]. The update also seeks to provide guidelines that are applicable to patients who are being evaluated for initial opioid prescription treatment as well as those who have been on opioids for continuous pain management [59].

4.4. Early intervention and screening for substance use disorders

Early intervention seeks to lessen the negative effects of substance abuse, curb risky behaviours before they cause harm, enhance social and mental well-being, and stop the development of a problem that would require specialized services for substance use disorders [60]. This intervention should be given to adults and adolescents who exhibit symptoms of minor substance use disorders or who are at risk of doing so, to people who binge drink at least 5 (for men) or 4 (for women) drinks at least once in 30 days, to women who use substances while pregnant or to people who use while driving [61]. And ideally everyone who seeks medical attention—including primary, urgent, psychiatric, and emergency care—should be screened for substance abuse. These kinds of screening practice can assist in determining how severe a person's substance usage is and whether treatment for their illness is required. In these situations, conversations, screening tools, medical testing, and observation can all be used to accurately identify substance abuse. A number of validated screening tools have been created to assist non-specialty healthcare providers in determining if a patient has an active substance use problem or is at risk of developing one [60][61].

5. TREATMENT APPROACHES:

Opioid use disorder is among the major burdens suffered by communities across the globe. Opioids are substances that activate opioid receptors in the brain and body. Addictionrelated problems can arise not only with the use of illicit opioids, such as heroin, but also through misuse of prescribed opioid medications, including morphine. OUD is a disease characterized by loss of control of its use, craving for continued use, use in spite of adverse consequences, development of tolerance, and withdrawal symptoms. Therapeutic approaches to OUD include screening, engagement, appropriate assessment, diagnosis, consideration of level of care, acute management of overdose or withdrawal, treatment with medications, psychotherapeutic approaches, and community support [62][63][64]. Screening and Engagement Outside of treatment seeking or self-referred patients, initiation of treatment for OUD often depends on successful screening within primary care settings or emergency departments. There is much shame and stigma associated with addiction that makes many patients resistant to seeking help. Effectively engaging patients with OUD requires understanding, empathetic, non-judgmental approaches. The developers of motivational interviewing, Miller and Rollnick, have described an underlying spirit or mindset of partnership, acceptance, compassion, and evocation [65]. Several useful screening tools are available that can be incorporated into different care settings. Routine screening for SUDs in general medical settings normalizes addiction as a health issue [66]. Screening questionnaires facilitate the first step in identifying the potential need for additional assessment to properly guide treatment planning. When screening for OUD, it is critical to consider cooccurring medical and psychiatric conditions. OUD frequently co-occurs among persons with chronic pain, depression, anxiety, suicidal ideation, and vice versa [63][67]. Depending on use practices, injecting or insufflating opioids places individuals at greater risk of contracting HIV/AIDS and HCV. Individuals with OUD also often present with a history of hazardous use of multiple other substances [68]. Screening for and addressing these interconnected issues affords individuals the greatest opportunity for recovery [4].

Overview of Interventions The most widely available therapeutic setting for the treatment of OUD is the primary care clinic. There is increasing support for general practitioner office-based management of OUD utilizing buprenorphine, also frequently referred to as office-based opioid treatment (OBOT) [69]. However, in parallel to this, there are dedicated substance use disorder specialty practices utilizing medications for OUD commonly known as medication-assisted treatment (MAT) that can assist with more complicated patients. Of particular importance, psychotherapy should be referred to when receiving treatment for MAT for OUD, in particular, considering the prevalence of underlying trauma, anxiety, and depression. Multiple evidence-based talk therapy and counseling alternatives exist that should be supported for recovery from opioid use disorders. Somewhat unique to the disease of addiction is the strong presence of community-based recovery approaches including peer-support meetings, therapeutic housing, and treatment "drug" courts. Medications Assisted Treatment (MAT) When an OUD is identified and plans are in place to appropriately manage active intoxication or withdrawal, then consideration for medication treatment should be given.

5.1. Buprenorphine

Buprenorphine is a partial mu opioid receptor agonist with a high binding affinity and a long duration of action [70]. Studies comparing maintenance opioid agonist buprenorphine treatment to tapering and discontinuing the buprenorphine show lower rates of relapse in the buprenorphine maintenance groups [71]. Moderate to severe opioid use disorder can be effectively and safely managed with buprenorphine maintenance in most cases [72]. When prescribing buprenorphine, it is important to be aware of the potential for

precipitated withdrawal. Precipitated withdrawal occurs when a full mu opioid receptor agonist is present and buprenorphine's high binding affinity displaces the full agonists causing a rapid drop in the mu receptor activation from full to partial [73].

5.2. Naltrexone

A second widely available and frequently prescribed medication for OUD is long-acting injectable naltrexone. Naltrexone is a mu opioid receptor antagonist which is started orally once daily and if tolerated then is converted to the long acting injectable once monthly form. This treatment is sometimes preferable for individuals who are determined to completely avoid treatment with opioid agonists like buprenorphine and methadone. This medication does not lead to the physiologic dependence developed on opioid agonists like buprenorphine and methadone [74][75].

6. POLICY AND LEGISLATION:

Regulatory measures to control opioid prescriptions: The opioid crisis has become a significant public health challenge globally, particularly in countries like the United States, where opioid overprescription has contributed to widespread addiction and overdose deaths. In response, various regulatory measures have been implemented to control opioid prescriptions, aiming to reduce misuse while ensuring that patients with legitimate medical needs continue to receive appropriate care.

6.1. Prescription Drug Monitoring Programs (PDMPs)

PDMPs are state-run electronic databases used to track the prescribing and dispensing of controlled prescription drugs to patients. They are one of the most widely adopted regulatory measures to monitor and control opioid prescriptions. As of 2023, all 50 states in the U.S. have implemented PDMPs, with varying degrees of mandatory use by prescribers and dispensers. A study found that states with mandatory PDMP use saw a 30% reduction in opioid prescriptions compared to states without such mandates [76]. 6.2. Opioid Prescription Guidelines

The Centers for Disease Control and Prevention (CDC) released the "CDC Guideline for Prescribing Opioids for Chronic Pain" in 2016, which provides recommendations for primary care clinicians on opioid prescribing for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline emphasizes starting with the lowest effective dose, considering non-opioid alternatives, and closely monitoring patients. After the guideline was implemented, opioid prescriptions in the U.S. decreased by 19.5% from 2016 to 2018 [77].

6.3. Limits on Opioid Prescriptions

Many states have enacted laws limiting the duration and dosage of opioid prescriptions. For instance, in 2018, Florida passed a law restricting initial opioid prescriptions for acute pain to a 3-day supply, with a 7-day supply permitted if deemed medically necessary by the prescriber. A study from Massachusetts showed that after implementing a 7-day limit on initial opioid prescriptions in 2016, there was a 6.6% reduction in the number of patients receiving opioid prescriptions [78].

6.4. Educational Initiatives for Healthcare Providers

Continuing Medical Education (CME) programs focusing on safe opioid prescribing practices have become mandatory in many states. For example, the state of New York requires prescribers to complete a three-hour course on pain management, palliative care, and addiction every three years. Research shows that such educational initiatives can lead to a significant reduction in opioid prescribing. In one study, prescribers who completed a CME program reduced their opioid prescriptions by 50% within six months [79]. The Drug Enforcement Administration (DEA) in the United States organizes National Prescription Drug Take Back Days, which allow the public to safely dispose of unused or expired

prescription opioids. In April 2023, the DEA collected nearly 663,000 pounds (over 331 tons) of prescription drugs, preventing them from being misused [80]. Between 2013 and 2018, opioid prescription rates in the United States decreased by 33%, coinciding with the implementation of various regulatory measures. However, despite these efforts, the opioid crisis continues to evolve. While prescription opioid overdose deaths have declined, there has been a sharp increase in deaths involving synthetic opioids like fentanyl, which are often illicitly manufactured [49].

6.5. Policies promoting access to addiction treatment services

Access to addiction treatment services is critical in addressing the global substance use disorder (SUD) crisis. Governments and organizations worldwide have implemented various policies to expand and promote access to these services, ensuring that individuals struggling with addiction receive the necessary care and support.

One of the most significant policy developments in the United States has been the Affordable Care Act (ACA). Passed in 2010, the ACA expanded access to addiction treatment by including substance use disorder services as one of the ten essential health benefits that must be covered by all insurance plans. The ACA also strengthened the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008, requiring insurers to provide equal benefits for mental health and substance use disorder treatment as they do for medical and surgical care. As a result of these measures, the number of individuals receiving addiction treatment has notably increased. For instance, Medicaid expansion under the ACA led to a 37% increase in admissions to substance use treatment programs between 2013 and 2017 [81].

Medicaid expansion, a key component of the ACA, has also played a crucial role in improving access to addiction treatment services. As of 2023, 39 states and the District of Columbia have expanded Medicaid eligibility to include low-income adults, many of whom struggle with substance use disorders. Research indicates that Medicaid expansion is associated with increased access to medication-assisted treatment (MAT) for opioid use disorder (OUD). In expansion states, the number of Medicaid beneficiaries receiving MAT nearly doubled between 2014 and 2016 [81].

Another significant legislative effort is the Comprehensive Addiction and Recovery Act (CARA) of 2016, which addresses the opioid crisis through a multifaceted approach, including expanding access to addiction treatment services. CARA authorizes funding for a wide range of addiction services, such as evidence-based treatment, MAT, and recovery support services. In 2019, CARA received \$900 million in federal funding, with a significant portion allocated to expanding access to treatment and recovery services [82]. The Substance Abuse Prevention and Treatment Block Grant (SABG) is another federal program that provides funding to states to support community-based addiction prevention, treatment, and recovery services. SABG is one of the largest sources of federal funding for substance use disorder treatment, with \$1.9 billion allocated in 2021.

The 21st Century Cures Act, passed in 2016, also includes provisions to expand access to addiction treatment services by increasing funding for mental health and substance use disorder services and accelerating the approval of new medications for addiction treatment. The Act allocated \$1 billion over two years to the State Targeted Response to the Opioid Crisis Grants, which support opioid addiction treatment services, including MAT, counseling, and recovery support [83].

Finally, the SUPPORT for Patients and Communities Act, passed in 2018, expands the use of telemedicine for addiction treatment, particularly in rural areas where access to healthcare providers is limited. Telemedicine has been shown to improve access to treatment for opioid use disorder (OUD), especially during the COVID-19 pandemic,

when in-person visits were restricted. For example, the number of telehealth visits for substance use treatment increased by 4,000% from March 2019 to March 2020. The Act also allows for the prescription of MAT via telemedicine without an initial in-person visit, making it easier for patients to access life-saving medications like buprenorphine [84]. *6.6. Efforts to reduce the availability of illicit opioids*

Efforts to reduce the availability of illicit opioids have been a key component of global and national strategies to combat the opioid crisis. Law enforcement agencies, governments, and international organizations have implemented a variety of measures aimed at curbing the production, distribution, and sale of these dangerous substances. For instance, in the United States, the Drug Enforcement Administration (DEA) has been actively involved in dismantling large-scale drug trafficking operations [85]. In 2020 alone, the DEA seized over 60 million dosage units of fentanyl, a synthetic opioid that is 50 to 100 times more potent than morphine [85]. On a global scale, the United Nations Office on Drugs and Crime (UNODC) has reported significant successes in international cooperation to disrupt the supply chains of illicit opioids [86]. Between 2017 and 2019, joint operations led to the seizure of over 500 metric tons of heroin and morphine, substances often linked to the opioid crisis [86]. Additionally, the introduction of stricter regulations on precursor chemicals used in the production of synthetic opioids has been a crucial step. For example, China's decision in 2019 to classify all fentanyl-related substances as controlled substances has been associated with a decline in the amount of fentanyl seized at U.S. borders [87]. These concerted efforts have played a vital role in reducing the availability of illicit opioids and mitigating their impact on public health. 6.7. International approaches and their applicability to other regions

International approaches to combating the opioid crisis have demonstrated varying degrees of success, offering valuable insights for their applicability to other regions. For example, Portugal's decriminalization model, implemented in 2001, treats drug possession for personal use as a public health issue rather than a criminal offense. This approach has led to significant reductions in overdose deaths and drug-related HIV infections, with drugrelated deaths in Portugal among the lowest in the European Union at 6 per million in 2019, compared to the EU average of 23 per million [88]. Comparably, Switzerland's "four-pillar" approach-prevention, treatment, harm reduction, and law enforcement-has been effective in reducing the negative effects of opiate use [88]. Since the 1990s, there has been a significant decline in the number of new heroin users and an over 50% drop in overdose deaths [89]. These models show that controlling opioid usage and reducing its effects may be accomplished using harm reduction and public health-focused approaches. It could be advantageous to modify these strategies to match the particular cultural, social, and legal circumstances of other areas dealing with opioid problems, such as North America and some parts of Asia. These models' direct application to other locations is dependent upon the availability of strong healthcare systems, extensive social services, and political commitment, all of which are necessary for them to be successful [89].

7. INNOVATIVE SOLUTIONS AND FUTURE DIRECTIONS:

7.1. Advances in non-opioid pain management techniques

The goal of postoperative pain management is to provide the best possible analgesia to restore organ function while minimizing adverse effects quickly. Following surgery, effective treatment may lessen persistent discomfort. For the treatment of postoperative pain, multimodal or balanced analgesia—which combines opioids, NSAIDs, local anaesthetics, and other adjuvants—has been advised. The focus of this CME session is on several medication classes for the treatment of acute pain. *7.1.1. NSAIDs*

NSAIDs, like diclofenac, ketorolac, and ibuprofen, have analgesic, anti-inflammatory, and antipyretic effects by inhibiting COX-1 and COX-2, reducing acute inflammatory mediator production [90]. Specialized COX-2 inhibitors, commonly referred to as "coxibs," have been created to lessen gastrointestinal side effects and bleeding linked to conventional NSAIDs, such as celecoxib, etoricoxib, valdecoxib, parecoxib, and lumiracoxib [91]. When combined with PCA morphine, NSAIDs can provide 30-50% morphine sparing and enhance analgesia, although being less effective than opioids in treating pain. The combination of NSAIDs and morphine PCA decreased postoperative nausea and vomiting by 30% and sedation by 29% but had no discernible effect on respiratory depression, urine retention, or pruritus [92]. Long-term usage of COX-2 medicines still causes gastrointestinal side effects despite improving gastrointestinal safety. Two medications, rofecoxib and valdecoxib, were withdrawn in response to severe allergic responses and issues with cardiovasculitis as a result of recent discussions [90]. There are potential cardiovascular risks associated with COX-2 selective drugs, such as stroke and myocardial infarction. While novel COX-2 inhibitors may promote vascular thrombus formation by upsetting the balance between pro- and anti-platelet aggregation actions, non-selective NSAIDs can still decrease platelet aggregation [93]. According to the study, people under 70 undergoing cardiothoracic surgery may experience reduced pain scores and a reduced need for opioids when NSAIDs and opioids are combined [94]. NSAIDs may result in a range of skin responses, from minor rashes to more serious illnesses. In those who are vulnerable, they may potentially result in acute renal failure by impeding prostaglandin biosynthesis. In kidney-risk patients, COX-2 inhibitors can lower glomerular filtration rate and induce salt retention [95]. COX-2 inhibitors may be helpful, however non-selective NSAIDs may increase bleeding during or after surgery. Short-term NSAID use had no discernible impact on non-union, according to Reuben et al., but greater doses, a history of smoking, and two-level spinal fusions raised the risk of non-union [96]. 7.1.2. Acetaminophen (paracetamol)

Acetaminophen is a well-tolerated pain management agent with no renal or cardiovascular side effects, making it suitable for both NSAIDs and opioid-sparing roles. One well-researched medication that can lead to liver damage is paracetamol overdose [97]. It's a well-liked experimental model for evaluating possible medications to treat liver damage and encourage regeneration. It is a well-liked option due to its simplicity and therapeutic significance. Some recent advancements have been found to fight hepatotoxicity produced by acetaminophen.

7.1.2.1. Targeting p62 for Acetaminophen-induced Liver Injury (AILI)

The multidomain scaffold protein p62 is essential to several physiological functions, such as oxidative stress responses, cell death, and signal transduction pathways for cell survival. The PB1 domain, which facilitates p62 self-oligomerization and interacts with other proteins, is located at the N-terminus. A proteolytic system known as the N-end rule pathway uses single N-terminal amino acids to determine degrons known as N-degrons. In the UPS-linked N-end rule pathway for autophagic degradation of Nt-arginylated substrates, including protein aggregates, the ZZ domain of p62 is a structural and functional analogue of the UBR box in N-recognin's and stimulates both mitophagy and ER-phagy. Autophagy, a lysosomal degradation mechanism, facilitates the elimination of damaged mitochondria, stressed ER, and APAP-adducts, hence providing protection against AILI. There is evidence that autophagy can remove APAP-adducts using p62 in a selective manner. How p62 would be recruited to APAP-adducts is still unknown, though. Given that it can mediate p62's interaction with ubiquitin-positive APAP-adducts, the UBA domain is probably essential. Selective autophagic degradation is promoted by the

p62 ZZ domain's interaction with Nt-Arg residues, which facilitates p62 in complexes with payloads. By using 3D structural modelling of p62 and screening a library of 540,000 compounds, small molecules that act as p62 agonists and improve its selective autophagic degradation have been found. YTK-2205 has been demonstrated to guard against AILI in mice by encouraging ubiquitin protein aggregation autophagy, ER-phagy, and hepatic mitophagy without altering [98].

7.1.2.2. Targeting TFEB for AILI

The lysosome, a final component of autophagy that contains more than 50 acid hydrolases, is essential to autophagic breakdown. TFEB is an essential transcription factor that controls the expression of PGC-1a, a critical transcription coactivator, which in turn controls the genes involved in lysosome biogenesis and mitochondrial biogenesis [99][100]. The kinases ERK2, mTORC1, AKT, GSK3B, and PKCB regulate TFEB posttranslationally by phosphorylating amino acid residues at Ser142 and Ser211, which results in the binding of cytosolic chaperones [99][101]. On the other hand, in reaction to lysosomal Ca2+ release, calcineurin dephosphorylates TFEB at Ser142 and Ser211, encouraging its nuclear translocation [102]. After chronic plus binge alcohol therapy, recent studies have shown a new autophagic flux scenario in mouse livers and pancreases, which is characterized by impaired TFEB and insufficient autophagy settings [103]. Mice exposed to alcohol-induced pancreatitis and hepatitis are protected against by the pharmacological or genetic activation of TFEB [103]. In APAP mouse models, autophagy activation via mTORC1 inhibitors guards against AILI, and TFEB activation is triggered by mTORC1 inhibition, indicating that TFEB activation may also be advantageous for AILI. The study discovered that when APAP was administered to mice livers, TFEB levels in the liver dropped. TFEB overexpression or deletion that was unique to the liver either made AILI worse or prevented it. Through enhanced APAP-AD clearance, hepatic expression of Sqstm1, and increased mitochondrial biogenesis, activation of TFEB may provide protection against AILI [104]. Hepatic JNK activation is associated with AILI but is unaffected by p62 loss. The inhibition of APAP-induced JNK activation by TFEB overexpression implies that selective autophagy is not required. There could be a role for increased mitochondria biogenesis, as evidenced by TFEB's increased expression of PGC1a [104]. Since it may prevent protein and lipid synthesis, inhibiting mTORC1 may not be the best course of action for treating AILI in its late stage. Researchers have discovered mTOR-independent TFEB agonists as a solution to this problem. According to a study using cell-based imaging, co-treating APAP with salinomycin triggered TFEB and provided protection against AILI. Salinomycin, however, lost its protective effect two hours after APAP was administered, indicating that it might not be the best medication to treat AILI patients. Future studies ought to investigate salinomycin's activation mechanisms as well as additional off-target mechanisms. In mice, narirutin, a Chinese medicinal plant, protects against AILI by activating hepatic TFEB. It does not alter APAPinduced JNK activation, but it does lower hepatic APAP-AD and oxidative stress. As a TFEB activator that is mTORC1-independent, NR has potential for treating AILI [105]. Autophagy and lysosomal biogenesis are boosted when mTORC1 and TFEB are inhibited by torin 1 and narirutin. TFEB activation is a promising treatment for AILI because it decreases the formation of mitochondrial ROS and hepatocyte necrosis and may also limit JNK activation.

7.1.3. Regional Anaesthetic

The field of regional anaesthesia has advanced significantly in the last few years, and the gold standard for peripheral nerve blockage is now ultrasound-guided methods. Patient outcomes including severe morbidity and postoperative pain have improved as a result of this increased accessibility and usage. In addition to improving technical performance,

ultrasound guidance has created new methods such fascial plane blocks. Prolonged regional anaesthesia still presents challenges in terms of maximising benefits and minimising risk. Research on sustained-release local anaesthetic compounds, pharmacological adjuncts, and continuous catheter procedures is continuing [106]. 7.1.4. Anticonvulsants

Because neural pain resists conventional painkillers, it is difficult to treat this persistent type of pain brought on by nerve injury. Recent studies on neuropathic pain have demonstrated that neuroplasticity-the nervous system's capacity to adapt to outside stimuli-is essential to the development and maintenance of symptoms. Anticonvulsant medications are appropriate for treating neuropathic pain conditions. A clinical trialproven anticonvulsant, carbamazepine efficiently reduces pain by blocking ectopic discharges and lowering Na+ channel conductance. It is useful in the treatment of postherpetic neuralgia, severe diabetic neuropathy, and trigeminal neuralgia. Neuropathic pain is best treated with newer anticonvulsants such as gabapentin, which have demonstrated strong analgesic effects, especially in diabetic neuropathy and postherpetic neuralgia. The antinociceptive efficacy of phenytoin is poor to low, but lamotrigine has significant promise for controlling and modulating neuropathic pain. There are other medications with possible antihyperalgesic and antinociceptive properties, such as phenobarbital, clonazepam, valproic acid, topiramate, pregabalin, and tiagabine. Anticonvulsant drugs like gabapentin and carbamazepine are evolving in treating neuropathic pain, with further research and clinical trials enhancing their effectiveness [107].

7.1.5. Ketamine

Since it possesses therapeutic qualities and can be administered either alone or in conjunction with other medications, ketamine, a dissociative anaesthetic agent, has been used in clinical applications for fifty years. Due to its antagonistic action against the N-Methyl-D-aspartate receptor, it is widely used in a variety of clinical settings. Ketamine provides advantages over other sedatives and anaesthetics, including stable haemodynamics, a lesser risk of respiratory depression, and bronchodilation status. It can be dissolved through a variety of methods. Anaesthetic ketamine is being utilised more and more to treat depression and pain.

However, research reveals conflicting outcomes and adverse consequences, so care must be used when treating complex chronic problems. It mostly affects the central nervous system's NMDA receptors, while it also partially interacts with opioid receptors. Patients with high pain scores, such as those recovering from surgery and experiencing severe postoperative pain, benefit most from ketamine. Ketamine has proven to be a useful analgesic for severe burns, accidents, and war-related injuries.Ketamine is frequently used for grafting, excisions, and changes to burn dressings. Its benefit is that it gives sedoanalgesia without impairing breathing. Researchers have looked into how ketamine affects the way pain is managed both during and after surgery. Ketamine used during surgery lessens pain intensity and lessens the demand for opioids. It also lessens nausea experienced after surgery. Subanesthetic ketamine has been shown in a Cochrane study to lower postoperative morphine use and enhance results for nausea and vomiting. According to meta-analyses, continuous subanesthetic ketamine treatment reduces pain in comparison to conventional opioid therapy [108]. Analgesic ketamine has been used to treat chronic pain, a typical problem brought on by extended nociceptive stimulation, since the late 1990s. Its usage in chronic pain situations has increased due to its direct analgesic qualities, effectiveness in hyperalgesia, and tolerance to opiates. However, there is little conclusive evidence supporting ketamine's effectiveness in treating chronic pain, and the drug's numerous side effects and lack of supporting research raise questions about its long-term

use. Patients with chronic migraine, fibromyalgia, visceral pain, chronic peripheral and central neuropathic pain, chronic regional pain syndrome, phantom and ischaemic limb pain, and chronic migraine may find some short-term relief from pain with ketamine. In palliative care, ketamine is frequently used as a co-adjuvant medication in conjunction with opioids to enhance cancer pain management. It can be applied topically, subcutaneously, intrathecally, orally, and intravenously. Because of the dose-dependent adverse effects, low doses are recommended. By inhibiting the NMDA receptor, ketamine can have anticancer effects and improve the effectiveness of morphine in the treatment of cancer pain. When pain is resistant to opioids and adjuvant medications, it works well. Ketamine is the medication of choice in situations where opioid tolerance, inflammatory pain, neuropathic pain component, and depression are troublesome; nevertheless, performing trials in cancer patients is difficult. Prior to utilising ketamine for cancer treatment, it is advised to weigh the advantages against the disadvantages and expenses [108].

7.2. Development of abuse-deterrent formulations

Strong opioids have been used far more frequently for chronic non-cancer pain during the past 20 years, which has increased addiction, misuse, and overdoses. In response to concerns expressed in the US, opioid analgesics with abuse resistance or deterrent properties have been developed. The FDA assessed two products to prevent abuse: Embeda® and Acurox®. Similar to other opioid agonists, Embeda® is an extended-release morphine tablet that has sequestered naltrexone. It is also capable of abuse. However, in people who are tolerant to opioids, its release could cause withdrawal. 2010 saw the rejection of Acurox®, an immediate-release oxycodone pill with subtherapeutic niacin, because of worries about its potential benefits in preventing abuse [109]. The FDA decided that there was not enough evidence to support Opana's ADF label and approved OxyContin's abuse deterrent label. Other OpAs with ADF technology that have been reviewed are Nucynta, Oxecta, Embeda, and Suboxone. Physical barrier, aversion, extended release, and polymer-opioid conjugates are examples of current ADF technologies [110].

7.2.1. Abuse-deterrent Technologies

Currently, the market only offers the first three deterrent approaches listed below, however the FDA has identified seven potential general categories of abuse-deterrent technology:

- a. In addition to potentially changing the structure of the active ingredient, physical and chemical barriers are made to withstand the mechanical modification of opioids, inhibiting their release for intravenous injection or nasal inhalation [111].
- b. Combination tablets containing an agonist and an antagonist maintain their analgesic effects when consumed, but when administered intravenously or through the nose, they lessen the euphoric effects of opioids [111].
- c. When taken accidentally, Average Drugs (ADFs) might reduce the "likeability" of opioids by producing unpleasant side effects or burning sensations when ingested in excessive doses [111].
- d. Once inserted by medical professionals, unconventional opioid delivery systems such as subcutaneous implants or sustained-release depot injectable formulations—are difficult to work with [111].
- e. prodrugs, or novel molecules, that enter the gastrointestinal system experience chemical changes or enzymatic activation to release the opioid's active components12[111].

7.3. Role of telemedicine in expanding access to treatment

The opioid epidemic's detrimental consequences on health are still getting worse. In 2016, the number of overdose deaths attributable to opioids hit an all-time high of 42,249 [112]. It has been demonstrated that offering individuals with OUDs evidence-based medication-assisted treatment (MAT), which may include methadone, buprenorphine, or naltrexone, can cut their risk of death by up to 50%. One possible tactic to improve access to MAT medications in underprivileged rural communities is telemedicine. But in order to scale up, it's necessary to get beyond logistical, legal, and quality obstacles and link patients and providers.

7.3.1. MAT via Telemedicine

Right now, naltrexone and methadone are not the best options for MAT expansion via telemedicine in rural America. Buprenorphine has shown promise in decreasing opiate usage, death, and HIV and hepatitis C transmission. It can be given in office-based settings and increases patient retention. Buprenorphine prescriptions via telemedicine have demonstrated therapeutic promise; pilot programs have demonstrated enhanced mental and physical well-being as well as decreased usage of illegal drugs. In addition to these advantages, telemedicine can also save costs, improve convenience, and shorten travel times for patients, doctors, and the healthcare system. Still, there is a chronic scarcity of prescribers of buprenorphine in rural settings [113].

7.4. Ongoing research and emerging treatment:

Promising developments in treatment options for OUD have demonstrated potential in the ongoing battle against this persistent health issue. Appropriate medication-assisted therapy (MAT) has been modified to include monthly injectable buprenorphine, an extended-release injectable naltrexone, and office-based methadone maintenance. Numerous approaches, including biassed agonism at the G protein-coupled receptor (GPCR), gene-targeted therapy, and heroin vaccines, are being studied as therapeutics. However, the market viability of these treatments is constrained by pharmacologic, clinical, and practical obstacles [114].

8. CHALLENGES AND BARRIERS:

8.1. Addressing the stigma associated with addiction

Lazarus-like impact on psychological functioning has been disco, as well as alleviation from cravings and a blockade of bliss. The data supporting opioid agonist therapy—which includes methadone and buprenorphine-has increased dramatically over the past 50 years, and nations like China, Iran, and Israel have embraced it [115]. Evidence supports opioid agonist therapy, although only 8% of injecting drug users worldwide receive it, with considerable regional differences [116]. Over nineteen thousand people with opioid use disorder would still not receive treatment even if all available slots were filled. Mutual aid groups and counselling services frequently oppose drug therapy for drug addiction. Narcotics Anonymous groups prohibit the use of pharmacotherapy, implying through online forums and language that it is an essential aspect of treatment. The negative perception of opioid agonist therapy is compounded by press articles like "When Drug Treatment for Narcotic Addiction Never Ends," which characterise doctors as "legit drug dealers" [117]. It is widely accepted that opioid agonist therapy is safe and effective for treating opioid use disorder. Treatment outcomes are poor when behavioural therapies are used alone; more than 80% of patients relapse into drug use. Retention rates of 60%-80% are achieved with appropriately dosed agonist therapy; just 15% of patients continue to use illicit opioids [118]. Research indicates that for the maintenance of methadone and buprenorphine, greater dosages and flexible dosing regimens work better. Since tapering techniques might result in high rates of recurrence, an appropriate treatment length is essential to success. Treatment length improves long-term results, and proactive commencement of opioid agonist therapy can be beneficial for patients with complex medical conditions. Clinically and financially successful, methadone and buprenorphine can save healthcare expenses by 50% to 62%. Buprenorphine adherence lowers annual total healthcare costs by about \$20,000 [119]. According to a recent cost-effectiveness analysis, every dollar that was saved increased by \$1.80. Opioid agonist therapy is a critical treatment for the opioid pandemic, according to research. It helps prevent new infections, lessen overdoses, and encourage abstinence. The primary obstacle, though, is the lack of acceptance and distribution of this evidence-based strategy. To make sure that research, not stigma, is the driving force behind this strategy, the medical community needs to take the lead.

8.2. Ensuring equitable access to treatment across different populations

The research validates that patients with MOUD who belong to racial/ethnic minorities e xperience more difficulties in obtaining naloxone and sterile syringes and that disparities are not explained by the intensity of opioid use nor by sociodemographic factors. The majority of patients were able to obtain harm reduction programs, as evidenced by the 7-27% of patients who reported disruptions in these services during the pandemic. However, access to sterile syringes and naloxone was uneven, which had an impact on marginalised communities. These services may be impacted by structural obstacles such unequal service delivery, medical mistrust, and a lack of childcare or transportation options [120]. According to the survey, 27% of MOUD patients reported service interruptions, raising questions about the potential effects of the pandemic's shift to virtual delivery. Minority group obstacles may have been lessened by this change, but universal barriers to access may have been introduced as well. Subsequent studies ought to look into particular obstacles that one in four MOUD patients face [121]. The interpretation of the study is constrained by multiple considerations. Participants in the volunteer survey might have encountered obstacles in accessing harm reduction interventions. Due to the small sample size, racial and ethnic minority groups may have been oversampled. The large confidence intervals may have resulted from the logit scale estimations' exponential transformation. It is not possible to draw conclusions regarding how interruptions affect the risk of overdose because the study is cross-sectional and does not include a control group. Future research will evaluate participants' places of residency and monitor the long-term effects of opioids [122]. According to this study, in the early months of the epidemic, Black, Hispanic, multiracial, Native American, Asian, and Pacific Islander MOUD patients reported having disproportionately trouble getting harm reduction programs. The results indicate that systematic studies of forms of oppression based on skin colour and nationality should be the main focus of future research.

8.3. Overcoming logistical and financial barriers in implementing prevention and treatment program 8.3.1. Logistical:

8.3.1.1. Patient identified

Logistical barriers to buprenorphine treatment include high out-of-pocket costs, provider waiting lists, and access to transportation and childcare. Most studies identified cost as a patient-identified barrier, except for a study in New York City where 90% had Medicaid coverage [123].

8.3.1.2. Provider identified

Although no studies have been conducted in VA settings, research indicates that the most frequent provider-identified obstacles to the prescription of OUD medications are logistical ones, with time being the most common barrier in 7/7 studies [124]. Because studies indicate that OUD patients are "difficult" to treat, negative attitudes regarding OUD patients among clinicians may heighten worries about time commitment and worry of an

overabundance of requests for buprenorphine [125]. According to an Ohio research, providers who have exemptions for buprenorphine accept insurance payments for a range of treatments; however, just 52.7% of them take insurance for buprenorphine. This underscores the possibility of restricted treatment availability, particularly for patients unable to cover treatment costs out of pocket, and emphasises the necessity for VHA to collaborate with community providers in remote regions [126].

8.3.2. Financial

This study highlights the financial hardship experienced by those seeking mental health services (MOUD) by examining the effects of OUD treatment expenses on everyday living and rehabilitation in Texas. The study emphasizes the necessity of extending Medicaid coverage under the Patient Protection and Affordable Care Act to lower the cost of OUD treatment and enable people to set aside money for indirect expenses. Grants are a limited resource, so OUD patients may suffer if they wait to apply for them [127]. According to this study, people with opioid use disorder (OUD) may suffer from "Financial Toxicity," which is the term used to describe the psychological impact of treatment expenditures and the financial burden associated with the illness. To reliably determine financial toxicity in OUD patients and identify individuals who may benefit from early treatment termination, a validated tool is required. The study may not apply to rural or less publicly financed areas due to its shortcomings, which include selection, recollection, and social desirability biases [128].

CONCLUSION:

The opioid crisis represents a profound public health emergency that is driven by misuse of both prescription and illicit opioids, which further accentuates the rising rates of addiction, overdose, and mortality. This calls for an integrated approach using evidencebased prevention techniques, innovative treatment modalities, and comprehensive policy initiatives. Key elements of the response included increased access to medication-assisted treatments, effective prescription monitoring programs, and community involvement that addressed the real socioeconomic determinants of health. For all these activities, health professionals, and especially pharmacists, are crucial for patient education, prescription management, and the delivery of life-saving interventions such as naloxone. This review, through the implementation of coordinated strategies by health, education, and social services, aspires to highlight routes that would lead to timely intervention and recovery in front of a never-ending opioid epidemic crisis. The ultimate call would be for continuous commitment to research, policy reform, and community participation toward the multifaceted challenges this crisis arises with. The devastating impact of opioid misuse and addiction upon individuals, families, and communities globally can only begin to be imagined by following a comprehensive, collective strategy that may mitigate or reduce such an impact.

REFERENCES:

- [1] Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. Am J Public Health 2018;108:182–6. https://doi.org/10.2105/AJPH.2017.304187.
- [2] Saloner B, McGinty EE, Beletsky L, Bluthenthal R, Beyrer C, Botticelli M, et al. A Public Health Strategy for the Opioid Crisis. Public Health Rep 2018;133:24S-34S. https://doi.org/10.1177/0033354918793627.
- [3] Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The Opioid Crisis: a Comprehensive Overview. Curr Pain Headache Rep 2018;22:16. https://doi.org/10.1007/s11916-018-0670-z.
- [4] Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and Treatment of Opioid Misuse and Addiction. JAMA Psychiatry 2019;76:208. https://doi.org/10.1001/jamapsychiatry.2018.3126.
- [5] Rummans TA, Burton MC, Dawson NL. How Good Intentions Contributed to Bad Outcomes: The Opioid Crisis. Mayo Clin Proc 2018;93:344–50. https://doi.org/10.1016/j.mayocp.2017.12.020.

- [6] Volkow ND, Blanco C. The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry 2021;26:218–33. https://doi.org/10.1038/s41380-020-0661-4.
- [7] Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. Annu Rev Public Health 2015;36:559–74. https://doi.org/10.1146/annurev-publhealth-031914-122957.
- [8] Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K. The opioid crisis: Origins, trends, policies, and the roles of pharmacists. Am J Heal Pharm 2019;76:424–35. https://doi.org/10.1093/ajhp/zxy089.
- [9] Coussens NP, Sittampalam GS, Jonson SG, Hall MD, Gorby HE, Tamiz AP, et al. The Opioid Crisis and the Future of Addiction and Pain Therapeutics. J Pharmacol Exp Ther 2019;371:396–408. https://doi.org/10.1124/jpet.119.259408.
- [10] Sheridan JL. Overview of this issue: "Pain management in an opioid crisis." Int J Clin Pharm 2021;43:309–12. https://doi.org/10.1007/s11096-021-01245-y.
- [11] Bandyopadhyay S. An 8,000-year History of Use and Abuse of Opium and Opioids: How That Matters For A Successful Control Of The Epidemic? (P4.9-055). Neurology 2019;92. https://doi.org/10.1212/WNL.92.15_supplement.P4.9-055.
- [12] Alpert A, Evans W, Lieber EMJ, Powell D. Origins of the Opioid Crisis and Its Enduring Impacts. Cambridge, MA: 2019. https://doi.org/10.3386/w26500.
- [13] Friedman SR, Krawczyk N, Perlman DC, Mateu-Gelabert P, Ompad DC, Hamilton L, et al. The Opioid/Overdose Crisis as a Dialectics of Pain, Despair, and One-Sided Struggle. Front Public Heal 2020;8. https://doi.org/10.3389/fpubh.2020.540423.
- [14] Lim TY, Stringfellow EJ, Stafford CA, DiGennaro C, Homer JB, Wakeland W, et al. Modeling the evolution of the US opioid crisis for national policy development. Proc Natl Acad Sci 2022;119. https://doi.org/10.1073/pnas.2115714119.
- [15] Blanco C, Wiley TRA, Lloyd JJ, Lopez MF, Volkow ND. America's opioid crisis: the need for an integrated public health approach. Transl Psychiatry 2020;10:167. https://doi.org/10.1038/s41398-020-0847-1.
- [16] Levine M, Fraser M. Elements of a Comprehensive Public Health Response to the Opioid Crisis. Ann Intern Med 2018;169:712. https://doi.org/10.7326/M18-1757.
- [17] Ash N, Tuten J, Bohenek W, Latham B. A comprehensive approach to addressing the opioid epidemic in a large health system. Am J Heal Pharm 2021;78:320–6. https://doi.org/10.1093/ajhp/zxaa388.
- [18] Compton WM, Wiley T, Blanco C. The Importance of Learning Health Systems in Addressing the Opioid Crisis. J Gen Intern Med 2020;35:891–4. https://doi.org/10.1007/s11606-020-06267-2.
- [19] Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study. PLOS Med 2019;16:e1002922. https://doi.org/10.1371/journal.pmed.1002922.
- [20] Battista NA, Pearcy LB, Strickland WC. Modeling the Prescription Opioid Epidemic. Bull Math Biol 2019;81:2258–89. https://doi.org/10.1007/s11538-019-00605-0.
- [21] Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol 2018;58:143–59. https://doi.org/10.1146/annurev-pharmtox-010617-052534.
- [22] Kertesz SG, Gordon AJ. A crisis of opioids and the limits of prescription control: United States. Addiction 2019;114:169–80. https://doi.org/10.1111/add.14394.
- [23] Maclean JC, Mallatt J, Ruhm C, Simon K. Economic Studies on the Opioid Crisis: A Review. Cambridge, MA: 2020. https://doi.org/10.3386/w28067.
- [24] Pardo B, Taylor J, Caulkins J, Reuter P, Kilmer B. The dawn of a new synthetic opioid era: the need for innovative interventions. Addiction 2021;116:1304–12. https://doi.org/10.1111/add.15222.
- [25] Manchikanti L. Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic. Pain Physician 2018;1:309–26. https://doi.org/10.36076/ppj.2018.4.309.
- [26] Taylor J, Pardo B, Hulme S, Bouey J, Greenfield V, Zhang S, et al. Illicit synthetic opioid consumption in Asia and the Pacific: Assessing the risks of a potential outbreak. Drug Alcohol Depend 2021;220:108500. https://doi.org/10.1016/j.drugalcdep.2020.108500.
- [27] Monnat SM. The contributions of socioeconomic and opioid supply factors to U.S. drug mortality rates: Urban-rural and within-rural differences. J Rural Stud 2019;68:319–35. https://doi.org/10.1016/j.jrurstud.2018.12.004.
- [28] Ivanich JD, Weckstein J, Nestadt PS, Cwik MF, Walls M, Haroz EE, et al. Suicide and the opioid overdose crisis among American Indian and Alaska Natives: a storm on two fronts demanding swift action. Am J Drug Alcohol Abuse 2021;47:527–34. https://doi.org/10.1080/00952990.2021.1955895.

- [29] Altekruse SF, Cosgrove CM, Altekruse WC, Jenkins RA, Blanco C. Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC). PLoS One 2020;15:e0227966. https://doi.org/10.1371/journal.pone.0227966.
- [30] Chapman A, Verdery AM, Monnat SM. Opioid misuse and family structure: Changes and continuities in the role of marriage and children over two decades. Drug Alcohol Depend 2021;222:108668. https://doi.org/10.1016/j.drugalcdep.2021.108668.
- [31] Singh GK, Kim, Jr. IE, Girmay M, Perry C, Daus GP, Vedamuthu IP, et al. Opioid Epidemic in the United States: Empirical Trends, and A Literature Review of Social Determinants and Epidemiological, Pain Management, and Treatment Patterns. Int J Matern Child Heal AIDS 2019;8:89–100. https://doi.org/10.21106/ijma.284.
- [32] Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, et al. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend 2019;200:59–63. https://doi.org/10.1016/j.drugalcdep.2019.03.014.
- [33] Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain Misconceptions and Mitigation Strategies. N Engl J Med 2016;374:1253–63. https://doi.org/10.1056/NEJMra1507771.
- [34] Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:1445–52. https://doi.org/10.15585/mmwr.mm655051e1.
- [35] Biancuzzi H, Dal Mas F, Brescia V, Campostrini S, Cascella M, Cuomo A, et al. Opioid Misuse: A Review of the Main Issues, Challenges, and Strategies. Int J Environ Res Public Health 2022;19:11754. https://doi.org/10.3390/ijerph191811754.
- [36] Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D, et al. Increases in heroin overdose deaths 28 States, 2010 to 2012. MMWR Morb Mortal Wkly Rep 2014;63:849–54.
- [37] O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016. MMWR Morb Mortal Wkly Rep 2017;66:1197–202. https://doi.org/10.15585/mmwr.mm6643e1.
- [38] Nataraj N, Rikard SM, Zhang K, Jiang X, Guy GP, Rice K, et al. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder. JAMA Netw Open 2024;7:e244617. https://doi.org/10.1001/jamanetworkopen.2024.4617.
- [39] Spencer M, Garnett M, Miniño A. Drug Overdose Deaths in the United States, 2002-2022. Atlanta, GA: 2023. https://doi.org/10.15620/cdc:135849.
- [40] Liang TJ, Ward JW. Hepatitis C in Injection-Drug Users A Hidden Danger of the Opioid Epidemic. N Engl J Med 2018;378:1169–71. https://doi.org/10.1056/NEJMp1716871.
- [41] Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol 2015;39:561–5. https://doi.org/10.1053/j.semperi.2015.08.013.
- [42] Schiller EY, Goyal A, Mechanic OJ. Opioid Overdose. 2024.
- [43] Patel S, Sheikh A, Nazir N, Monro S, Anwar A. The Opioid Crisis: How to Lessen the Burden on Emergency Departments by At-risk Populations. Cureus 2020. https://doi.org/10.7759/cureus.11498.
- [44] Rzasa Lynn R, Galinkin J. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9:63–88. https://doi.org/10.1177/2042098617744161.
- [45] Cheetham A, Picco L, Barnett A, Lubman DI, Nielsen S. The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. Subst Abuse Rehabil 2022;Volume 13:1–12. https://doi.org/10.2147/SAR.S304566.
- [46] Kulesza M. Substance Use Related Stigma: What we Know and the Way Forward. J Addict Behav Ther Rehabil 2013;02. https://doi.org/10.4172/2324-9005.1000106.
- [47] Newman BN, Crowell KA. The intersectionality of criminality and substance use self-stigmas. Stigma Heal 2023;8:212–22. https://doi.org/10.1037/sah0000293.
- [48] El-Bassel N, Shoptaw S, Goodman-Meza D, Ono H. Addressing long overdue social and structural determinants of the opioid epidemic. Drug Alcohol Depend 2021;222:108679. https://doi.org/10.1016/j.drugalcdep.2021.108679.
- [49] Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths United States, 2013–2017. MMWR Morb Mortal Wkly Rep 2018;67. https://doi.org/10.15585/mmwr.mm675152e1.
- [50] Livingston JD, Milne T, Fang ML, Amari E. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction 2012;107:39–50. https://doi.org/10.1111/j.1360-0443.2011.03601.x.
- [51] Corrigan PW, Schomerus G, Shuman V, Kraus D, Perlick D, Harnish A, et al. Developing a research

agenda for reducing the stigma of addictions, part II: Lessons from the mental health stigma literature. Am J Addict 2017;26:67–74. https://doi.org/10.1111/ajad.12436.

- [52] Barry CL, McGinty EE, Pescosolido BA, Goldman HH. Stigma, Discrimination, Treatment Effectiveness, and Policy: Public Views About Drug Addiction and Mental Illness. Psychiatr Serv 2014;65:1269–72. https://doi.org/10.1176/appi.ps.201400140.
- [53] Lefebvre RC, Chandler RK, Helme DW, Kerner R, Mann S, Stein MD, et al. Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing communities study. Drug Alcohol Depend 2020;217:108338. https://doi.org/10.1016/j.drugalcdep.2020.108338.
- [54] Al-Astal A-EY, Sodhi K, Lakhani HV. Optimization of Prescription Drug Monitoring Program to Overcome Opioid Epidemic in West Virginia. Cureus 2022. https://doi.org/10.7759/cureus.22434.
- [55] Delcher C, Pauly N, Moyo P. Advances in prescription drug monitoring program research: a literature synthesis (June 2018 to December 2019). Curr Opin Psychiatry 2020;33:326–33. https://doi.org/10.1097/YCO.00000000000608.
- [56] Hildebran C, Cohen DJ, Irvine JM, Foley C, O'Kane N, Beran T, et al. How Clinicians Use Prescription Drug Monitoring Programs: A Qualitative Inquiry. Pain Med 2014;15:1179–86. https://doi.org/10.1111/pme.12469.
- [57] Chua K-P, Brummett CM, Conti RM, Haffajee RL, Prosser LA, Bohnert ASB. Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids. JAMA Netw Open 2019;2:e193673. https://doi.org/10.1001/jamanetworkopen.2019.3673.
- [58] Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. Prescribing Opioids for Pain The New CDC Clinical Practice Guideline. N Engl J Med 2022;387:2011–3. https://doi.org/10.1056/NEJMp2211040.
- [59] Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Reports 2022;71:1–95. https://doi.org/10.15585/mmwr.rr7103a1.
- [60] Center for Substance Abuse Treatment. Brief Interventions and Brief Therapies for Substance Abuse. 1999.
- [61] Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US). Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. 2016.
- [62] Galanter M. The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Fourth Edition. 2008.
- [63] Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Prim 2020;6:3. https://doi.org/10.1038/s41572-019-0137-5.
- [64] Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med 2015;9:358–67. https://doi.org/10.1097/ADM.00000000000166.
- [65] Miller, William R. Rollnick S. Motivational interviewing: Helping people change (3rd edition). 2013.
- [66] Agerwala SM, McCance-Katz EF. Integrating Screening, Brief Intervention, and Referral to Treatment (SBIRT) into Clinical Practice Settings: A Brief Review. J Psychoactive Drugs 2012;44:307–17. https://doi.org/10.1080/02791072.2012.720169.
- [67] Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet 2019;393:1760–72. https://doi.org/10.1016/S0140-6736(18)33078-2.
- [68] Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry 2021;26:41–50. https://doi.org/10.1038/s41380-020-00949-3.
- [69] Donroe JH, Bhatraju EP, Tsui JI, Edelman EJ. Identification and Management of Opioid Use Disorder in Primary Care: an Update. Curr Psychiatry Rep 2020;22:23. https://doi.org/10.1007/s11920-020-01149-0.
- [70] Shulman M, Wai JM, Nunes E V. Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs 2019;33:567–80. https://doi.org/10.1007/s40263-019-00637-z.
- [71] No Title n.d. https://doi.org/10.1016/j.jsat.2014.12.011.
- [72] Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence. JAMA Intern Med 2014;174:1947. https://doi.org/10.1001/jamainternmed.2014.5302.
- [73] JOHNSON R. Buprenorphine: how to use it right. Drug Alcohol Depend 2003;70:S59–77. https://doi.org/10.1016/S0376-8716(03)00060-7.
- [74] Lee JD, Nunes E V, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT):

a multicentre, open-label, randomised controlled trial. Lancet 2018;391:309–18. https://doi.org/10.1016/S0140-6736(17)32812-X.

- [75] Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction 2018;113:1188–209. https://doi.org/10.1111/add.14180.
- [76] Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse? Pain Med 2012;13:434–42. https://doi.org/10.1111/j.1526-4637.2012.01327.x.
- [77] Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain— United States, 2016. JAMA 2016;315:1624. https://doi.org/10.1001/jama.2016.1464.
- [78] Hill M V., McMahon ML, Stucke RS, Barth RJ. Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures. Ann Surg 2017;265:709–14. https://doi.org/10.1097/SLA.00000000001993.
- [79] Berland D, Rodgers P. Rational use of opioids for management of chronic nonterminal pain. Am Fam Physician 2012;86:252–8.
- [80] U.S. Department of Justice DEA (DEA). National Prescription Drug Take Back Day. 2023.
- [81] Saloner B, Karthikeyan S. Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. JAMA 2015;314:1515. https://doi.org/10.1001/jama.2015.10345.
- [82] Wen H, Hockenberry JM, Borders TF, Druss BG. Impact of Medicaid Expansion on Medicaidcovered Utilization of Buprenorphine for Opioid Use Disorder Treatment. Med Care 2017;55:336– 41. https://doi.org/10.1097/MLR.00000000000703.
- [83] Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health 2015;105:e55–63. https://doi.org/10.2105/AJPH.2015.302664.
- [84] Lin L (Allison), Fernandez AC, Bonar EE. Telehealth for Substance-Using Populations in the Age of Coronavirus Disease 2019. JAMA Psychiatry 2020;77:1209. https://doi.org/10.1001/jamapsychiatry.2020.1698.
- [85] Drug Enforcement Administration (DEA). 2020 National Drug Threat Assessment. 2021.
- [86] United Nations Office on Drugs and Crime. World Drug Report 2020. 2020.
- [87] U.S. Customs and Border Protection. CBP Reports Decline in Fentanyl Seizures Following China's Classification of All Fentanyl-Related Substances. 2020.
- [88] European Monitoring Centre for Drugs and Drug Addiction. Portugal: Country Drug Report 2021. 2021.
- [89] Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction 2010;105:29–37. https://doi.org/10.1111/j.1360-0443.2009.02741.x.
- [90] Beaulieu P. Non-opioid strategies for acute pain management. Can J Anesth Can d'anesthésie 2007;54:481–5. https://doi.org/10.1007/BF03022036.
- [91] Langford RM. Pain management today—what have we learned? Clin Rheumatol 2006;25:2–8. https://doi.org/10.1007/s10067-006-0311-5.
- [92] Marret E, Kurdi O, Zufferey P, Bonnet F, Warltier DC. Effects of Nonsteroidal Antiinflammatory Drugs on Patient-controlled Analgesia Morphine Side Effects. Anesthesiology 2005;102:1249–60. https://doi.org/10.1097/00000542-200506000-00027.
- [93] Steinman MA, McQuaid KR, Covinsky KE. Age and rising rates of cyclooxygenase-2 inhibitor use. J Gen Intern Med 2006;21:245–50. https://doi.org/10.1111/j.1525-1497.2006.00336.x.
- [94] Bainbridge D, Cheng DC, Martin JE, Novick R. NSAID-analgesia, pain control and morbidity in cardiothoracic surgery. Can J Anesth Can d'anesthésie 2006;53:46–59. https://doi.org/10.1007/BF03021527.
- [95] Harris RC. COX-2 and the Kidney. J Cardiovasc Pharmacol 2006;47:S37–42. https://doi.org/10.1097/00005344-200605001-00007.
- [96] Reuben SS, Ablett D, Kaye R. High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Can J Anesth Can d'anesthésie 2005;52:506–12. https://doi.org/10.1007/BF03016531.
- [97] Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E. Paracetamol: A Review of Guideline Recommendations. J Clin Med 2021;10:3420. https://doi.org/10.3390/jcm10153420.
- [98] Hinz K, Niu M, Ni H-M, Ding W-X. Targeting Autophagy for Acetaminophen-Induced Liver Injury: An Update. Livers 2024;4:377–87. https://doi.org/10.3390/livers4030027.
- [99] Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 2013;14:283–96. https://doi.org/10.1038/nrm3565.
- [100] Chao X, Wang S, Zhao K, Li Y, Williams JA, Li T, et al. Impaired TFEB-Mediated Lysosome

Biogenesis and Autophagy Promote Chronic Ethanol-Induced Liver Injury and Steatosis in Mice. Gastroenterology 2018;155:865-879.e12. https://doi.org/10.1053/j.gastro.2018.05.027.

- [101] Settembre C, Di Malta C, Polito VA, Arencibia MG, Vetrini F, Erdin S, et al. TFEB Links Autophagy to Lysosomal Biogenesis. Science (80-) 2011;332:1429–33. https://doi.org/10.1126/science.1204592.
- [102] Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol 2015;17:288–99. https://doi.org/10.1038/ncb3114.
- [103] Wang S, Ni H-M, Chao X, Ma X, Kolodecik T, De Lisle R, et al. Critical Role of TFEB-Mediated Lysosomal Biogenesis in Alcohol-Induced Pancreatitis in Mice and Humans. Cell Mol Gastroenterol Hepatol 2020;10:59–81. https://doi.org/10.1016/j.jcmgh.2020.01.008.
- [104] Chao X, Niu M, Wang S, Ma X, Yang X, Sun H, et al. High-throughput screening of novel TFEB agonists in protecting against acetaminophen-induced liver injury in mice. Acta Pharm Sin B 2024;14:190–206. https://doi.org/10.1016/j.apsb.2023.10.017.
- [105] Fang Z, Xu Y, Liu G, Shao Q, Niu X, Tai W, et al. Narirutin activates TFEB (transcription factor EB) to protect against Acetaminophen-induced liver injury by targeting PPP3/calcineurin. Autophagy 2023;19:2240–56. https://doi.org/10.1080/15548627.2023.2179781.
- [106] Albrecht E, Chin KJ. Advances in regional anaesthesia and acute pain management: a narrative review. Anaesthesia 2020;75. https://doi.org/10.1111/anae.14868.
- [107] Tremont-Lukats IW, Megeff C, Backonja M-M. Anticonvulsants for Neuropathic Pain Syndromes. Drugs 2000;60:1029–52. https://doi.org/10.2165/00003495-200060050-00005.
- [108] Abdollahpour A, Saffarieh E, Zoroufchi B. A review on the recent application of ketamine in management of anesthesia, pain, and health care. J Fam Med Prim Care 2020;9:1317. https://doi.org/10.4103/jfmpc_jfmpc_875_19.
- [109] Schaeffer T. Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics. J Med Toxicol 2012;8:400–7. https://doi.org/10.1007/s13181-012-0270-y.
- [110] Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend 2014;138:1–6. https://doi.org/10.1016/j.drugalcdep.2014.02.006.
- [111] Litman RS, Pagán OH, Cicero TJ. Abuse-deterrent Opioid Formulations. Anesthesiology 2018;128:1015–26. https://doi.org/10.1097/ALN.00000000002031.
- [112] Holly Hedegaard, Arialdi M. Miniño and MW. Drug Overdose Deaths in the United States, 1999– 2017. 2018.
- [113] Yang YT, Weintraub E, Haffajee RL. Telemedicine's Role in Addressing the Opioid Epidemic. Mayo Clin Proc 2018;93:1177–80. https://doi.org/10.1016/j.mayocp.2018.07.001.
- [114] Bruera E, Paice JA. Cancer Pain Management: Safe and Effective Use of Opioids. Am Soc Clin Oncol Educ B 2015:e593–9. https://doi.org/10.14694/EdBook_AM.2015.35.e593.
- [115] Kermode M, Crofts N, Kumar MS, Dorabjee J. Opioid substitution therapy in resource-poor settings. Bull World Health Organ 2011;89:243–243. https://doi.org/10.2471/BLT.11.086850.
- [116] Dole VP. A Medical Treatment for Diacetylmorphine (Heroin) Addiction. JAMA 1965;193:646. https://doi.org/10.1001/jama.1965.03090080008002.
- [117] William L. White. Narcotics Anonymous and the Pharmacotherapeutic Treatment of Opioid Addiction in the United States. 2011.
- [118] Bart G. Maintenance Medication for Opiate Addiction: The Foundation of Recovery. J Addict Dis 2012;31:207–25. https://doi.org/10.1080/10550887.2012.694598.
- [119] Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship Between Buprenorphine Adherence and Health Service Utilization and Costs Among Opioid Dependent Patients. J Subst Abuse Treat 2014;46:456– 62. https://doi.org/10.1016/j.jsat.2013.10.014.
- [120] Collins AB, Ndoye CD, Arene-Morley D, Marshall BDL. Addressing co-occurring public health emergencies: The importance of naloxone distribution in the era of COVID-19. Int J Drug Policy 2020;83:102872. https://doi.org/10.1016/j.drugpo.2020.102872.
- [121] Bergman BG, Kelly JF. Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond. J Subst Abuse Treat 2021;120:108152. https://doi.org/10.1016/j.jsat.2020.108152.
- [122] Brooklyn JR, Sigmon SC. Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. J Addict Med 2017;11:286–92. https://doi.org/10.1097/ADM.00000000000310.
- [123] Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract 2015;10:2.

https://doi.org/10.1186/s13722-014-0023-0.

- [124] McDonald KM, Rodriguez HP, Shortell SM. Organizational Influences on Time Pressure Stressors and Potential Patient Consequences in Primary Care. Med Care 2018;56:822–30. https://doi.org/10.1097/MLR.00000000000974.
- [125] Huhn AS, Dunn KE. Why aren't physicians prescribing more buprenorphine? J Subst Abuse Treat 2017;78:1–7. https://doi.org/10.1016/j.jsat.2017.04.005.
- [126] Parran T V, Muller JZ, Chernyak E, Adelman C, Delos Reyes CM, Rowland D, et al. Access to and Payment for Office-Based Buprenorphine Treatment in Ohio. Subst Abus Res Treat 2017;11:117822181769924. https://doi.org/10.1177/1178221817699247.
- [127] McCarty D, Gu Y, McIlveen JW, Lind BK. Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis. Addict Sci Clin Pract 2019;14:31. https://doi.org/10.1186/s13722-019-0160-6.
- [128] Black N. Patient reported outcome measures could help transform healthcare. BMJ 2013;346:f167–f167. https://doi.org/10.1136/bmj.f167.